Consistent with the AKT signaling pathway being a potential target after ZNF217 overexpression, our lab identified the Akt inhibitor triciribine as the only drug tested in vivo that has shown the potential to decrease tumor burden in a human breast xenograft with high ZNF217 expression [2, 12]. This evidence concerns the gene ZNF217 and neoplasm.